{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'CLINICAL STUDY PROTOCOL', 'KCP-330-023', 'A PHASE 3 RANDOMIZED, CONTROLLED, OPEN-LABEL', 'STUDY OF SELINEXOR, BORTEZOMIB, AND', 'DEXAMETHASONE (SVD) VERSUS BORTEZOMIB AND', 'DEXAMETHASONE (VD) IN PATIENTS WITH RELAPSED OR', 'REFRACTORY MULTIPLE MYELOMA (RRMM)', 'Study Name: BOSTON: Bortezomib, Selinexor, and Dexamethasone in Patients with', 'Multiple Myeloma', 'Study Number:', 'KCP-330-023', 'Study Phase:', '3', 'Investigational Product:', 'Selinexor (KPT-330)', 'EudraCT Number:', '2016-003957-14', 'Indication:', 'Relapsed or refractory multiple myeloma (RRMM)', 'Sponsor:', 'Karyopharm Therapeutics Inc.', '85 Wells Avenue', 'Newton, MA 02459 USA', 'Tel. + (617)658-0600', 'Protocol Date and Version:', '18 November 2016, Version 1.0', '22 February 2017, Version 2.0 (Amendment 1)', '06 April 2017, Version 3.0 (Amendment 2)', '17 August 2018, Version 4.0 (Amendment 3)', 'CONDUCT', 'In accordance with the ethical principles that originate from the Declaration of Helsinki and', 'that are consistent with International Council for Harmonisation (ICH) guidelines on Good', 'Clinical Practice (GCP) and regulatory requirements as applicable.', 'CONFIDENTIAL INFORMATION', 'This document is the sole property of Karyopharm Therapeutics Inc. (Karyopharm). This', 'document and any and all information contained herein has to be considered and treated as', 'strictly confidential. This document shall be used only for the purpose of the disclosure herein', 'provided. No disclosure or publication shall be made without the prior written consent of', 'Karyopharm.', 'Confidential', 'Page 1', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'PROTOCOL APPROVAL SIGNATUREPAGE', 'SPONSOR: KARYOPHARM THERAPEUTICSINC.', 'I have read and understand the contents of this clinical protocol for Study KCP-330-023 dated', '17 August 2018 and agree to meet all obligations of Karyopharm Therapeutics Inc., as detailed', 'in all applicable regulations and guidelines. In addition, I will inform the Principal Investigator', 'and all other Investigators of all relevant information that becomes available during the conduct', 'of this Study.', 'Approved By:', 'PPD', '17 August 2018', 'PPD', 'MD', 'Date', 'PPD', 'Karyopharm Therapeutics Inc.', '17 August 2018', 'PPD', 'PhD, MBA', 'Date', 'PPD', 'Karyopharm Therapeutics Inc.', 'Confidential', 'Page 2', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'PROTOCOL APPROVAL SIGNATURE PAGE', 'SPONSOR: KARYOPHARM THERAPEUTICS INC.', '1 have read and understand the contents of this clinical protocol for Study KCP-330-023 dated', '17 August 2018 and agree to meet all obligations of Karyopharm Therapeutics Inc., as detailed', 'in all applicable regulations and guidelines. In addition, I will inform the Principal Investigator', 'and all other Investigators of all relevant information that becomes available during the conduct', 'of this Study.', 'Approved By:', '17 August 2018', 'PPD', 'MD', 'Date', 'PPD', 'Karyopharm Therapeutics Inc.', 'PPD', '17 August 2018', 'PPD', 'PhD, MBA', 'Date', 'PPD', 'Karyopharm Therapeutics Inc.', 'Confidential', 'Page 2', 'Version 4.0']\n\n###\n\n", "completion": "END"}